Results 231 to 240 of about 12,689 (257)

Incremental Cost-Effectiveness Ratio of Alteplase in Patients with Acute Myocardial Infarction in the French Setting

PharmacoEconomics, 1997
On the basis of data collected from general hospital centres in France on 704 patients initially presenting with acute myocardial infarction, the mean 1-year cost of treatment was calculated to be 52,160 French francs (F) per patient (1994 values). This was independent of whether the patient received thrombolysis, and included all costs associated with
A, Pelc, J, Dardenne, J H, Frelon, G, Hanania   +3 more
openaire   +2 more sources

Determination of incremental cost-effectiveness ratios of antitumor drugs

Farmaciya (Pharmacy), 2021
Tat'jana Sergeevna Teptsova, Kristina Andreevna Perova, Nuriya Zagitovna Musina, Vitaliy Vladimirovich Omelyanovsky, Georgiy Rubenovich Khachatryan   +4 more
openaire   +1 more source

[Non-parametric methods for estimating confidence intervals around the incremental cost-effectiveness ratio].

Epidemiologia e prevenzione, 2008
In recent years, cost-effectiveness analysis has become a frequent component of randomized clinical trials. In statistical terms, the major efforts addressed the method for estimating the Incremental Cost Effectiveness Ratio (ICER) and its confidence interval both with parametric and non-parametric methods.
PETRINCO M, GREGORI, DARIO, LAZZARATO F, BRUNELLO F, VELTRI A, BERCHIALLA P, PAGANO E.   +6 more
openaire   +2 more sources

Decision-making with the incremental cost-effectiveness ratio under uncertainty

2006
Cet article concerne l'applicabilité des régions de confiance du ratio coût-efficacité incrémental (RCEI) à la prise de décision dans les évaluations médico-économiques, qui est loin d'être directe, car deux RCEI identiques peuvent être associés à des conclusions opposées.
de Peretti, Christian, Siani, Carole
openaire   +1 more source

Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs

Current Oncology, 2021
Ronak Saluja, Tina Jiao, Matthew C Cheung   +2 more
exaly  

4CPS-029 Pembrolizumab, nivolumab and atezolizumab: incremental cost-effectiveness ratio

Section 7: Post Congress additions, 2022
R Tamayo Bermejo, JC Del Río Valencia, B Mora Rodríguez, I Muñoz Castillo   +3 more
openaire   +1 more source

Incremental Cost-Effectiveness Ratio (ICER)

2013
Marie Boltz, Holly Rau, Paula Williams, Holly Rau, Paula Williams, Jane Upton, Jos A. Bosch, Victoria E. Burns, Jos A. Bosch, Leila Anane, Jos A. Bosch, Joanna Long, Barbara Mullan, Peter M. Gollwitzer, Gabriele Oettingen, Kelly Winter, Jason S. Yeh, Susannah D. Copland, Douglas Carroll, Austin S. Baldwin, Valerie G. Loehr, Linda C. Baumann, Alyssa Karel, Mark T. Drayson, Anna C. Phillips, Pamela A. Geller, Alexandra Nelson, Nicolas Rohleder, Jutta M. Wolf, Yukari Tanaka, Shin Fukudo, Yoshiyuki Takimoto, J. Rick Turner, Laura Rodriguez-Murillo, Rany M. Salem, Wendy Troxel, Martica H. Hall, Elizabeth Galik, Yoshiyuki Takimoto, Adriana Carrillo, Della Matheson, Alan M. Delamater, Janine Sanchez, Luigi Meneghini, Margaret A. Chesney, David E. Anderson, Peter A. Hall, Nicolas Rohleder, Neil Schneiderman, Ulf-Dietrich Reips, Timothy W. Smith, Bert N. Uchino, Kimberly Bowen, McKenzie Carlisle, Maija Reblin, Rebecca Campo, Nelli Hankonen, Nikola Stenzel, Stefan Krumm, Jonathan Newman, Kevin S. Masters, Bart Verkuil, J. F. Brosschot, J. Rick Turner, Tomohiko Muratsubaki, Shin Fukudo, Siqin Ye, Anthony Remaud   +67 more
openaire   +1 more source

Incremental net benefit of whole genome sequencing for newborns and children with suspected genetic disorders: Systematic review and meta-analysis of cost-effectiveness evidence

Health Policy, 2022
Mario Cesare Nurchis, Maria TERESA Riccardi, Francesca Clementina Radio   +2 more
exaly  

Incremental cost-effectiveness of extracorporeal membranous oxygenation as a bridge to cardiac transplant or left ventricular assist device placement in patients with refractory cardiogenic shock

JTCVS Open, 2022
Scott Silvestry
exaly  

Incremental Cost-Effectiveness Ratio

2010
openaire   +1 more source